Find recruiting clinical trials for Parkinson's in the UK � from early-stage disease-modifying therapies to advanced treatment options. See where trials fit into your care pathway.
Free to use � Live data from ClinicalTrials.gov � Updated daily
Answer a few questions about your condition and we'll match you to the most relevant clinical trials.
See where clinical trials fit into your care journey
When symptoms first require medication
Standard: Levodopa (co-beneldopa/co-careldopa), dopamine agonists (pramipexole, ropinirole), or MAO-B inhibitors (rasagiline, selegiline)
When levodopa wears off or causes unpredictable responses
Standard: COMT inhibitors (entacapone, opicapone), MAO-B inhibitors, or dopamine agonists added to levodopa
For significant motor complications despite optimised oral therapy
Standard: Apomorphine infusion, levodopa-carbidopa intestinal gel (LCIG), or deep brain stimulation (DBS)
Trials aiming to slow or stop disease progression � the Holy Grail of Parkinson's research
Standard: No approved disease-modifying treatment yet � trials are critical
A progressive neurological condition caused by the loss of dopamine-producing cells in the brain. Affects about 153,000 people in the UK. Symptoms include tremor, stiffness, slowness of movement, and balance problems.
Current treatments manage symptoms but don't slow progression. Clinical trials are testing disease-modifying therapies, gene therapies, focused ultrasound, and novel drug delivery systems that could transform outcomes.
Parkinson's also causes sleep problems, depression, anxiety, constipation, and cognitive changes. Many trials now target these non-motor symptoms, which can be as debilitating as the movement problems.
Loading trials from ClinicalTrials.gov...
Novel approaches include GBA-targeted therapies, LRRK2 inhibitors, gene therapy (AADV-GAD, VY-AADC), GLP-1 agonists (diabetes drugs repurposed for PD), focused ultrasound, and alpha-synuclein immunotherapy.
Yes. Disease-modifying trials are a major focus. Several drugs targeting specific genetic forms of Parkinson's (GBA, LRRK2 mutations) aim to slow or halt progression rather than just treat symptoms.
Yes. Gene therapy trials study delivering genes to produce dopamine or protect brain cells. Approaches include AAV-based gene delivery targeting the substantia nigra. UK centres are involved in several studies.
Use our search above to find trials that match your condition and location. Review the eligibility criteria carefully.
Talk to your GP or specialist about any trials you are interested in. They can help determine if a trial is appropriate for you.
Reach out to the trial team directly using the contact information on the ClinicalTrials.gov listing. They will guide you through screening.
If you meet the criteria and decide to participate, you will go through informed consent and begin the trial process.